SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones
14 janv. 2021 08h30 HE
|
SELLAS Life Sciences Group
- Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe - - License Agreement with 3D Medicines for Development and...
SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications
21 déc. 2020 08h30 HE
|
SELLAS Life Sciences Group
- Early Data from Study of GPS in Combination with Keytruda® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks and 100% Progression...
SELLAS Strengthens Year-End Balance Sheet with Addition of Approximately $30.5 Million
17 déc. 2020 08h30 HE
|
SELLAS Life Sciences Group
- Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing - - Improved Cash Position Will Support Clinical Development Programs for...
SELLAS Announces Pricing of $16.2 Million Registered Direct Offering
13 déc. 2020 20h10 HE
|
SELLAS Life Sciences Group
NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
11 déc. 2020 08h30 HE
|
SELLAS Life Sciences Group
– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment – – Statistically Significant Difference of Duration of Immune Response of NPS vs. Control: p=0.000094 - – Data to be...
SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China
07 déc. 2020 08h30 HE
|
SELLAS Life Sciences Group
- SELLAS to Potentially Receive Up To $202 Million, Inclusive of $7.5 Million Upfront License Fee and $8 Million Near-term Milestones, plus Tiered Royalties - - 3D Medicines to Lead Clinical...
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2020 Financial Results
13 nov. 2020 16h32 HE
|
SELLAS Life Sciences Group
- Received IMPD Approval to Commence Enrollment in France for Pivotal Phase 3 Study of Galinpepimut-S in Acute Myeloid Leukemia Patients - - Strengthened Balance Sheet During Quarter with...
SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia
09 sept. 2020 08h30 HE
|
SELLAS Life Sciences Group
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results
13 août 2020 16h30 HE
|
SELLAS Life Sciences Group
- Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market -- Clinical programs for galinpepimut-S, including phase 3 REGAL study, on track, with multiple...
SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market
31 juil. 2020 13h30 HE
|
SELLAS Life Sciences Group
NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...